YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
In the latest close session, Recursion Pharmaceuticals (RXRX) was down 3.14% at $4.63. This move lagged the S&P 500's daily gain of 0.58%. Meanwhile, the Dow experienced a rise of 0.49%, and the technology-dominated Nasdaq saw an increase…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change HeartBeam Inc. 184,339,116 0.9388 0.6611 0.7064 +0.2718 Alector Inc. 67,48…
[short sale] abluecup As October begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 39 stocks with short interest above 20% of shares outstandi…
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.70, marking a -1.2% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.77%. On the other hand, the Dow registered a loss…
Recursion Pharmaceuticals RXRX continues to leverage its AI-native drug discovery platform through a broad portfolio of pharma, technology and data partnerships. These collaborations are expanding its pipeline while generating non-dilutive…
Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation. The fresh funding, which was led by Catalio Capital Management, with participation from Iconiq…
Recursion Pharmaceuticals (RXRX) closed at $4.05 in the latest trading session, marking a +2.02% move from the prior day. Elsewhere, the Dow saw a downswing of 0.36%, while the tech-heavy Nasdaq appreciated by 0.45%. Shares of the biotechn…
Goldman Sachs' Neutral initiation of Tempus AI, Inc. (NASDAQ:TEM) on September 21 puts the company's fastest-growing businesses under different tests: diagnostics offers visible near-term growth, while the data and applications segment fac…
CHICAGO, September 21, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a…
Recursion Pharmaceuticals (RXRX) is back on traders' screens after a sharp daily move, with the share price closing at US$3.83. Recent returns have been mixed over the past week and month. For context, Recursion Pharmaceuticals has deliver…
[Fearless girl statue standing against New York Stock Exchange Building] xavierarnau Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impac…
AstraZeneca AZN announced that the FDA accepted its regulatory filing seeking approval for its investigational enzyme replacement therapy (ERT) efzimfotase alfa to treat patients aged two years and older with hypophosphatasia (HPP). The FD…
Palantir Technologies (Nasdaq: PLTR) and Rocket Lab Corporation (Nasdaq: RKLB) are among the biggest climbers in the Roundtable 100 this week. While Palantir climbed 30 places to No. 33, Rocket Lab rose 34 places to No. 45. Sam Badawi expl…
Recursion Pharmaceuticals (RXRX) closed at $3.18 in the latest trading session, marking a -1.85% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.45% for the day. At the same time, the Dow lost 1.2…
[Reciprocal Tariffs] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - SEPTEMBER 14 * VOLATILITY WAT…
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.16, moving -1.71% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.59%. Meanwhile, the Dow experienced a drop of 0…
[FDA Headquarters] The Trump administration on Tuesday appointed the acting heads of the FDA units overseeing drugs, vaccines, and tobacco to permanent positions weeks after nominating White House advisor Heidi Overton as the agency's next…
Buying a stock that has significantly lagged broader equities is only a good idea when there are solid reasons to expect it will bounce back and perform better over the long run. But sometimes that simply isn't the case, and it's best to a…
[New York Stock Exchange pediment carving] Jean Suplicy Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MON…
It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 8.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earni…
Recursion Pharmaceuticals RXRX uses an AI-driven drug discovery platform, Recursion Operating System (OS), to identify and develop novel therapies across its pipeline. It is advancing several clinical-stage programs, with REC-4881 emerging…
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [http…
[US 100 dollar bill folded into an up arrow on wooden table. Illustration of the concept of inflation, profit, earning and investment] Biotech stocks have reached their highest level since the height of the pandemic after Moderna (MRNA [ht…
For Immediate Release Chicago, IL – August 18, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial m…
Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Artificial intelligence (AI) is poised to reshape pharmaceutical research by addressing some of the industry's most persistent challenges: lengthy timelines, high development costs and substantial clinical failure rates. Traditional drug d…
This article first appeared on GuruFocus. The supplied source only contains the heatmap headline and ticker list, without the underlying short-interest percentages or ranking data. I can write the story accurately from that limited informa…
Quick Read Tempus AI (TEM) hit five straight EPS beats with shares up 17%, as Twist Bioscience (TWST) logged 14 straight quarters of sequential revenue growth. Anthropic targets a September IPO with a healthcare AI pitch that could front-r…
Recursion Pharmaceuticals RXRX reported a loss of 25 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 23 cents. The company had incurred a loss of 41 cents per share in the year-ago quarte…
Recursion Pharmaceuticals, Inc. reported its Q2 2026 results, with revenue falling to US$7.67 million from US$19.22 million a year earlier, while its net loss narrowed to US$131.01 million and loss per share improved to US$0.25. Alongside…
(RTTNews) - RECURSION PHARMACEUTICALS, INC. (RXRX) released Loss for second quarter of -$131.005 million The company's earnings came in at -$131.005 million, or -$0.25 per share. This compares with -$171.897 million, or -$0.41 per share, l…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Recursion Pharmaceuticals stock has had a difficult run over the past several years, and the curr…
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.41 per share a year ago. These figures are adjusted for non-recurring…
Recursion Pharmaceuticals Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for drug…
Major earnings expected before the bell on Wednesday include: * The Walt Disney Company (DIS [https://seekingalpha.com/symbol/DIS]) * Eli Lilly and Company (LLY [https://seekingalpha.com/symbol/LLY]) * Shopify (SHOP [https://seekingalpha.c…
Salt Lake City, UT, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conf…